Protara Therapeutics (TARA) Non Operating Interest Expenses (2013 - 2014)

Protara Therapeutics (TARA) has reported Non Operating Interest Expenses for 5 consecutive years, with $411000.0 the latest figure, recorded in Q4 2018.

• In Q4 2018, Non Operating Interest Expenses rose 3.01% year-over-year to $411000.0; the TTM figure through Dec 2018 stood at $411000.0 (up 3.01% YoY), while the FY2018 annual figure was $411000.0, up 3.01% from the prior year.
• Non Operating Interest Expenses advanced to $411000.0 in Q4 2018 per TARA's latest filing, from $399000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $544000.0 in Q4 2016 and bottomed at $27000.0 in Q4 2015.
• Historically, Non Operating Interest Expenses has averaged $371800.0 across 5 years, with a median of $411000.0 in 2018.
• Annual changes were most pronounced in 2015 — Non Operating Interest Expenses plunged 94.35% — and 2016, when it soared 1914.81%.
• Protara Therapeutics' Non Operating Interest Expenses stood at $478000.0 in 2014, then slumped by 94.35% to $27000.0 in 2015, then jumped by 1914.81% to $544000.0 in 2016, then fell by 26.65% to $399000.0 in 2017, then gained by 3.01% to $411000.0 in 2018.
• Business Quant data shows TARA's Non Operating Interest Expenses at $411000.0 in Q4 2018, $399000.0 in Q4 2017, and $544000.0 in Q4 2016.